Protocol Ledger

NCT05516758 · Phase II · TERMINATED

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Interventional Phase II clinical trial protocol NCT05516758 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-31 Enrollment: 491 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05516758
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)491 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05516758
Protocol FieldVerified Registry Value
NCT IdentifierNCT05516758
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment491 participants (ACTUAL)
Registered Start Date2022-08-31
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI